Related Experiment Video
Updated: May 25, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
Published on: August 10, 2017
MMP-2 selectivity in hydroxamate-type inhibitors
P Serra1, M Bruczko, J M Zapico
1Department of Chemistry, Universidad CEU San Pablo, Madrid, Spain.
Abstract:
Extracellular matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases involved in physiological and pathological processes, through the cleavage of extracellular matrix. MMPs are capable of degrading essentially all matrix components, which is crucial for malignant tumor growth, invasion, metastasis and angiogenesis. The vertebrates MMP family includes at least 26 enzymes (23 have been known in humans) with only MMP-1, 2, and 7 experimentally validated as targets for antitumoral drug design. However, inhibition of MMP-1 has been hypothesized to be the cause of the clinically observed musculoskeletal syndrome when broad spectrum inhibitors are used. On the other hand, MMP-9 is a tricky enzyme, since its inhibition might be useful in treating patients with early-stage cancers, but MMP-9 is an anti-target in patients with advanced disease. So, MMP-9 inhibition should also be prevented. Therefore, selective MMP-2 inhibition arises as a pursued profile for MMP binders. Among them, hydroxamates have been extensively studied as small molecule drug candidates characterized by an effective zinc-binding group plus additional side chains responsible for the selectivity. This article pays particular attention to MMP-2 selectivity on hydroxamate-type inhibitors, especially against MMP-9, and their chemical structure, SAR, general synthetic methods, and molecular modelling studies are here reviewed in order to inspire further design of new effective anticancer agents.
Insights
Selective inhibition of matrix metalloproteinase-2 (MMP-2) is a promising anticancer strategy. Hydroxamates offer selectivity, particularly against MMP-9, guiding the design of novel antitumoral agents.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Extracellular matrix metalloproteinases (MMPs) are enzymes crucial for tumor growth, invasion, and angiogenesis.
- Targeting specific MMPs is key for effective anticancer drug design, as broad-spectrum inhibition can cause adverse effects.
- MMP-9 inhibition presents a dual role, beneficial in early-stage cancers but detrimental in advanced disease, necessitating careful consideration.
Purpose of the Study:
- To review hydroxamate-type inhibitors with a focus on MMP-2 selectivity.
- To explore the chemical structure, structure-activity relationships (SAR), synthesis, and molecular modeling of these inhibitors.
- To provide insights for designing novel anticancer agents targeting MMP-2.
Main Methods:
- Review of existing literature on hydroxamate-based MMP inhibitors.
- Analysis of chemical structures and SAR data for MMP-2 selective compounds.
- Examination of synthetic methodologies and molecular modeling studies.
Main Results:
- Hydroxamates demonstrate potential as selective MMP-2 inhibitors, particularly against MMP-9.
- Understanding the SAR of hydroxamate inhibitors is crucial for achieving desired selectivity.
- Molecular modeling aids in the rational design of potent and selective MMP-2 inhibitors.
Conclusions:
- Selective MMP-2 inhibition is a viable strategy for anticancer drug development.
- Hydroxamates represent a promising class of compounds for achieving MMP-2 selectivity.
- Further research into hydroxamate-based inhibitors can lead to the development of effective new anticancer therapies.
Related Concept Videos
Composition of Polyprotic Acid Solutions as a Function of pH
A graph with the alpha values is plotted against the volume of base added during titration. Here, a...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Enzyme Inhibition
Role of Matrix Metalloproteases in Degradation of ECM
A...

